Kevin Hay is a hematologist at the Arthur J.E. Child Comprehensive Cancer Centre and Associate Professor in Medicine at the University of Calgary with a focus on development and translation of adoptive cell therapies. He completed his MSc and MD at the University of Manitoba, before undergoing Internal Medicine and Hematology training at UBC. He then took a postdoctoral fellowship position at Fred Hutchinson Cancer Research Center (Seattle, USA) before returning to Canada as an Assistant Professor at UBC in the BC Cancer Leukemia, Blood, and Marrow Transplant Program. While in BC he developed a CAR-T research program and continues to serve as Medical Director of the BC Cancer Conconi Family Immunotherapy Laboratory (Victoria, Canada), which is dedicated to the manufacturing of cellular immunotherapies. He moved to Calgary in Fall 2023 to join the Riddell Centre for Cancer Immunotherapy and continues to lead biomanufacturing efforts, clinical research, and a research laboratory focused on improving cellular immunotherapies.

Kevin Hay is a hematologist at the Arthur J.E. Child Comprehensive Cancer Centre and Associate Professor in Medicine at the University of Calgary with a focus on development and translation of adoptive cell therapies. He completed his MSc and MD at the University of Manitoba, before undergoing Internal Medicine and Hematology training at UBC. He then took a postdoctoral fellowship position at Fred Hutchinson Cancer Research Center (Seattle, USA) before returning to Canada as an Assistant Professor at UBC in the BC Cancer Leukemia, Blood, and Marrow Transplant Program. While in BC he developed a CAR-T research program and continues to serve as Medical Director of the BC Cancer Conconi Family Immunotherapy Laboratory (Victoria, Canada), which is dedicated to the manufacturing of cellular immunotherapies. He moved to Calgary in Fall 2023 to join the Riddell Centre for Cancer Immunotherapy and continues to lead biomanufacturing efforts, clinical research, and a research laboratory focused on improving cellular immunotherapies.